Plain-English translation of NCT07010432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new injectable medication called to see how it affects bone health in women over 50 who have gone through menopause and have obesity. When people lose weight, their bones can become weaker — and this is especially common in postmenopausal women. The study will compare the medication to an already-approved weight loss drug (), a combination of both treatments, and a placebo (dummy injection) to find out which approach best protects bone while helping people lose weight.
Postmenopausal women who lose weight often experience a decline in bone density, which can increase their risk of fractures and osteoporosis. Researchers want to know whether this new treatment can help people lose weight while protecting their bones at the same time.
You likely qualify if…
You likely don't qualify if…
You will receive once-weekly injections under your skin for about 79 weeks (roughly 18 months). The first 16 weeks involve gradually increasing doses to find the right level for you, then you'll stay on a steady dose for 52 weeks while following a reduced-calorie diet. You'll be randomly assigned to receive either the new medication, an approved weight loss drug, a combination of both, or a placebo — and neither you nor the researchers will know which one you're getting. Throughout the study, you'll have regular visits to monitor your bone health, weight, and overall well-being.
AI-generated summary from trial data · Oct 4, 2026 · Not medical advice
Denmark